Vedolizumab
Top View
- Tocilizumab Intravenous – (M0004)
- The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: a Review of the Current Literature
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Evaluation and Management of Suspected Immune-Mediated
- (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
- Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis Pietro Diana, MD1, Charoen Mankongpaisarnrung, MD2, Michael B
- Vedolizumab) for Injection, for Intravenous Use for Injection: 300 Mg Vedolizumab in a Single-Dose Vial
- VACCINE GUIDELINES for IMMUNOCOMPROMISED and OTHER SPECIAL POPULATIONS I. GENERAL PRINCIPLES COVID-19 Immunization Is Recommen
- Entyvio® (Vedolizumab)
- Entyvio (Vedolizumab) C6773-A
- Clinical Guidance on COVID- 19 Vaccines for Persons with Inflammatory Bowel Disease
- Infliximab-Refractory Checkpoint Colitis
- Beyond Anti‐Tnfs: Positioning of Other Biologics for Crohn's Disease
- Entyvio® (Vedolizumab)
- NCL JFC Minutes June 2020
- New Trials in Ulcerative Colitis Therapies
- Ulcerative Colitis Treatment Options Brochure | ENTYVIO (Vedolizumab)
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances